ReoPro

(Abciximab)

ApprovedMonoclonal antibody

Abciximab is used to prevent blood clots and reduce the risk of heart attack or other serious heart problems in patients undergoing certain heart procedures, particularly angioplasty.[2] ReoPro is currently approved and in use across 15 indications[4].[1]

ReoPro is one of 308 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

307

Competitors

Pipeline

Status by Indication[4][1]

Indication

Coronary Artery DiseaseActive, not recruiting

Intermediate Coronary SyndromeUnknown

StrokeActive, not recruiting

Acute Coronary SyndromeActive, not recruiting

Angina PectorisUnknown

Acute Myocardial InfarctionActive, not recruiting

MortalityActive, not recruiting

ST Elevation Myocardial InfarctionActive, not recruiting

Myocardial InfarctionActive, not recruiting

Recurrent ThrombophlebitisUnknown

Coronary Artery DiseasePreclinical

Active, not recruiting

Intermediate Coronary SyndromePreclinical

Unknown

StrokePhase 3

Active, not recruiting

Acute Coronary SyndromeApproved

Active, not recruiting

Angina PectorisPreclinical

Unknown

Acute Myocardial InfarctionPhase 3

Active, not recruiting

MortalityApproved

Active, not recruiting

ST Elevation Myocardial InfarctionPhase 3

Active, not recruiting

Myocardial InfarctionPhase 3

Active, not recruiting

Recurrent ThrombophlebitisPreclinical

Unknown

Showing 10 of 15 indications

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

ReoPro

Boehringer Ingelheim

Approved

3 2

Zometa

Pfizer

Preclinical

1 3

Folvite

Eli Lilly

Preclinical

1 4

Proamatine

Repatha

Pradaxa

3 7

Botox

RRevance Therapeutics, Inc.

Preclinical

2 8

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Zantac 150

CChattem

Preclinical

1 10

Alka-Seltzer

AAbbott

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myocardial Infarction4 trials

Randomized Trial of Standard vs ClearWay-infused Abciximab and Thrombectomy for Myocardial Infarction

Unknown status·CCLI Foundation·Phase 4·NCT01499407·128 enrolled

Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction

Completed·UUniversity of Leipzig·Phase 3·NCT00712101·1,912 enrolled

Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO)

Unknown status·UUniversity Medical Center Groningen·N/A·NCT00927615·534 enrolled

Show 1 more trial

Myocardial Infarction With ST-Elevation

Unknown status·UUniversity Hospital, Strasbourg, France·Phase 3·NCT00638638·292 enrolled

Stroke3 trials

Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis

Terminated·UUniversity of Zurich·Phase 3·NCT00126139·100 enrolled

Abciximab in Wake-up Stroke

Terminated·UUniversity of Zurich·Phase 3·NCT00167765·50 enrolled

Stroke Prevention With Abciximab in Carotid Endarterectomy

Withdrawn·UUniversity of Rochester·Phase 1/2·NCT00178451

Efficacy and Safety3 trials

Exploratory P2 Trial to Evaluate Efficacy and Safety of Clotinab® (Abciximab) in Acute MI Patients

Unknown status·IISU Abxis Co., Ltd.·Phase 2·NCT03087539·146 enrolled

A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty

Completed·CCentocor, Inc.·Phase 3·NCT00269893·2,038 enrolled

A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty

Completed·CCentocor, Inc.·Phase 3·NCT00269906·1,265 enrolled

Randomized3 trials

A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI

Completed·—·Phase 4·NCT00440895·74 enrolled

A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI

Completed·LLaval University·Phase 4·NCT00440778·105 enrolled

FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or Abciximab

Completed·UUniversity of Bologna·Phase 4·NCT00383136·692 enrolled

ST Elevation Myocardial Infarction2 trials

Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)

Completed· GSK logo

GSK·Phase 3·NCT00426751·429 enrolled

Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Elevation Myocardial Infarction

Completed·CCatharina Ziekenhuis Eindhoven·Phase 4·NCT00986050·907 enrolled

14 more indications

Percutaneous Coronary Intervention2 trials

A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.

Completed·CCentocor, Inc.·Phase 3·NCT00269880·2,792 enrolled

Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock

Completed·—·Phase 4·NCT00420030·80 enrolled

Microvascular Function1 trial

A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function

Unknown status·UUniversity of Melbourne·N/A·NCT02105870·40 enrolled

Diabetes Mellitus1 trial

Tailored Antiplatelet Therapy During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus

Completed·SSeoul National University Bundang Hospital·Phase 4·NCT01475552·130 enrolled

Clopidogrel1 trial

Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3)

Completed·DDeutsches Herzzentrum Muenchen·Phase 4·NCT00133250·800 enrolled

Pain1 trial

Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis

Withdrawn·SSt. Louis University·Phase 2·NCT01932554

Prevention1 trial

Below Study - Balloonangioplasty or Stents With ReoPro for Prevention of Subacute Reocclusion in Arteries Below the Knee

Unknown status·UUniversity Hospital Tuebingen·Phase 2·NCT00163254

Intravenous1 trial

Intravenous Versus Intracoronary Use of Abciximab

Completed·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT00685464·355 enrolled

Efficacy1 trial

Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty

Completed·UUniversity of Pisa·Phase 4·NCT00354406·110 enrolled

Acute Coronary Syndrome1 trial

Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)

Completed·DDeutsches Herzzentrum Muenchen·Phase 4·NCT00133003·2,022 enrolled

Ischemic stroke1 trial

A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)

Terminated·CCentocor, Inc.·Phase 3·NCT00073372·808 enrolled

Mortality1 trial

Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen

Terminated·AAzienda Sanitaria Ospedaliera·Phase 4·NCT00320229·84 enrolled

ART1 trial

EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study

Completed·LLaval University·Phase 4·NCT00169819·1,000 enrolled

Acute Myocardial Infarction1 trial

Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02181985·5,989 enrolled

Unspecified1 trial

Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients

Completed·EEmory University··NCT00379418·220 enrolled

Sources

References

[1]
ClinicalTrials.gov — 30 trial records for Abciximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — ReoPro drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Abciximab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Abciximab. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Integrin Alpha-Iib/beta-3 Inhibitor; Integrin Alpha-V/beta-3 Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Boehringer Ingelheim

ReoPro

Status by Indication[4][1]

Competitive Landscape

Trials by Indication[1]

Myocardial Infarction4 trials

Stroke3 trials

Efficacy and Safety3 trials

Randomized3 trials

ST Elevation Myocardial Infarction2 trials

Percutaneous Coronary Intervention2 trials

Microvascular Function1 trial

Diabetes Mellitus1 trial

Clopidogrel1 trial

Pain1 trial

Prevention1 trial

Intravenous1 trial

Efficacy1 trial

Acute Coronary Syndrome1 trial

Ischemic stroke1 trial

Mortality1 trial

ART1 trial

Acute Myocardial Infarction1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News